SCHEMBL17100772

SCHEMBL17100772

Cc1ccccc1CN1CCN(c2nc(-c3ccc(Cl)cc3)no2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.59
ALDH1A1 P00352 6/20 0.59
LMNA P02545 5/20 0.59
KDM4E B2RXH2 3/20 0.59
SMN1; SMN2 Q16637 4/20 0.52
RAB9A P51151 3/20 0.52
NPC1 O15118 2/20 0.52
HTT P42858 2/20 0.52
POLB P06746 1/20 0.52
CYP2D6 P10635 3/20 0.51
CYP1A2 P05177 2/20 0.51
CYP2C19 P33261 2/20 0.51
MAPK1 P28482 1/20 0.51
TSHR P16473 2/20 0.50
HSD17B10 Q99714 1/20 0.50
MITF O75030 1/20 0.50
GAA P10253 2/20 0.49
CYP2C9 P11712 1/20 0.49
CNR1 P21554 1/20 0.47
CNR2 P34972 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17100591 0.91 MAPT (0.58) MAPTALDH1A1LMNAKDM4ESMN1; SMN2
SCHEMBL17115008 0.91 KMT2A (0.55) MAPTALDH1A1LMNAKDM4ESMN1; SMN2
SCHEMBL17100671 0.88 MAPT (0.56) MAPTALDH1A1LMNAKDM4ECYP2D6
SCHEMBL17100630 0.83 SMN1; SMN2 (0.59) MAPTALDH1A1LMNAKDM4ESMN1; SMN2
SCHEMBL17100858 0.83 LMNA (0.57) MAPTALDH1A1LMNAKDM4ESMN1; SMN2
SCHEMBL17100762 0.82 CYP2D6 (0.57) MAPTALDH1A1LMNAKDM4ESMN1; SMN2
SCHEMBL17100886 0.78 ALDH1A1 (0.49) MAPTALDH1A1LMNAKDM4ESMN1; SMN2
SCHEMBL17100673 0.78 ALDH1A1 (0.57) MAPTALDH1A1LMNASMN1; SMN2CYP2D6
SCHEMBL17100854 0.78 MAPT (0.59) MAPTALDH1A1LMNAKDM4ESMN1; SMN2
SCHEMBL14486340 0.78 LMNA (0.59) MAPTALDH1A1LMNAKDM4ERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 US claimed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US claimed
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 US disclosed
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 US disclosed
US-10562869-B2 Oxadiazole compounds REMYND NV (BE) 2020-02-18 US disclosed
US-10562869-B2 Oxadiazole compounds REMYND NV (BE) 2020-02-18 US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US disclosed
EP-3119774-A1 OXADIAZOLE COMPOUNDS reMynd NV (BE) 2017-01-25 EP disclosed
WO-2015140130-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2015-09-24 WO disclosed
WO-2015140130-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2015-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10562869-B2 Oxadiazole compounds OXA1L, PSEN1, MAPT MAPT 3/4885ALDH1A1 482/4885LMNA 760/4885
US-20200140400-A1 OXADIAZOLE COMPOUNDS OXA1L, PSEN1, MAPT MAPT 3/4885ALDH1A1 561/4885LMNA 748/4885
US-20170073319-A1 OXADIAZOLE COMPOUNDS OXA1L, PSEN1, MAPT MAPT 3/4885ALDH1A1 482/4885LMNA 760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.